Astellas Pharma Inc. experiences ups and downs as it shows significant activity in the biotech market. The company reported a new 12-month low, but also unveiled revised 2024 financial forecasts due to core business growth and impairment losses. New partnerships with Sangamo Therapeutics and YASKAWA, innovative agreements to deliver genomic medicines for neurological diseases and develop cell therapy systems were announced. Multiple regulatory approvals came through, including from FDA for DIGITIVA™ for heart failure, PADCEV™ in combination with KEYTRUDA® for advanced bladder cancer, and VYLOY™ (zolbetuximab) in combination with chemotherapy for advanced gastric and gastroesophageal junction cancer. However, an unsigned deal with MSN couldn't be enforced, and an indictment of an Astellas employee by China's prosecutors raised concerns. A research agreement with Invenra Inc. in therapeutic bispecific antibody discovery showcases their commitment to innovation. Despite openings of new facilities in Cambridge, Massachusetts and South San Francisco, there are concerns related to workers as Astellas Gene Therapies plans to close a biomanufacturing facility affecting around 100 employees.
Astellas Pharma Inc. News Analytics from Mon, 11 Oct 2021 07:00:00 GMT to Sat, 25 Jan 2025 23:43:47 GMT -
Rating -3
- Innovation 5
- Information 7
- Rumor -2
